S. Langdon

Igor Goryanin, Galina Lebedeva, Simon P. Langdon, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

David J Harrison, Alexey Goltsov, James Bown, 2012, Cellular signalling.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Igor Goryanin, David J Harrison, Alexey Goltsov, 2011, Cellular signalling.

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.

S. Langdon, H. Fiebig, R. Giavazzi, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Hilal S. Khalil, J. Bown, D. Harrison, 2015, Journal of biotechnology.

Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer

A. Turnbull, J. Fraser, L. Pang, 2020, Frontiers in Oncology.

The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines.

S. Guichard, J. Smyth, D. Jodrell, 2005, European journal of cancer.

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Igor Goryanin, Stuart Moodie, Galina Lebedeva, 2009, Cancer research.

Steroid hormones and cancer: (II) lessons from experimental system

S. Langdon, W. Miller, 1997 .

Steroid hormones and cancer: (III) observations from human subjects.

S. Langdon, W. Miller, 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium

P. Lambin, L. Dubois, A. Harris, 2015, Journal of enzyme inhibition and medicinal chemistry.

Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer.

C. Ward, D. Harrison, P. Mullen, 2014, Biochemical Society transactions.

Biocompatibility of common implantable sensor materials in a tumor xenograft model

Alan F. Murray, A. Tsiamis, C. Ward, 2018, Journal of biomedical materials research. Part B, Applied biomaterials.

The influence of type I collagen on the growth and differentiation of the human colonic adenocarcinoma cell line HT-29 in vitro.

J. Hickman, S. Langdon, J. East, 1992, Differentiation; research in biological diversity.

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

P. Sismondi, J. Bartlett, S. Love, 1996, British Journal of Cancer.

Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.

J. Smyth, S. Langdon, W. Miller, 1990, British Journal of Cancer.

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.

J. Smyth, S. Langdon, W. Miller, 1994, European journal of cancer.

CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.

H. Gabra, J. Smyth, S. Langdon, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients

H. Gabra, P. Vasey, J. Smyth, 2007, Clinical Cancer Research.

c‐erbb growth‐factor‐receptor proteins in ovarian tumours

H. Phillips, S. Langdon, W. Miller, 1995, International journal of cancer.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on‐target inhibitors Rapamycin, BEZ235, and LY294002

J. Bown, D. Harrison, S. Langdon, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Cancer Cell Culture

S. Langdon, 2003 .

Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

F. Couch, E. Swisher, J. Higgins, 2022 .

Growth factors and ovarian cancer

J. Smyth, S. Langdon, 1998 .

Transforming growth factor-beta isoform expression in human ovarian tumours.

D. Katsaros, J. Bartlett, S. Love, 1997, European journal of cancer.

Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.

C. Supuran, A. Scozzafava, J. Winum, 2012, Bioorganic & medicinal chemistry letters.

Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression

D. Cameron, S. Langdon, W. Miller, 1997, Breast Cancer Research and Treatment.

Antagonists of mitogenic peptides.

J. Cummings, J. Smyth, S. Langdon, 1994 .

Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.

T. Hupp, R. Nenutil, Nicola J. Maclaine, 2012, Journal of immunological methods.

University of Rochester--leaders in heavy metals.

J. Smyth, S. Langdon, W. Miller, 1993, Environmental health perspectives.

Edinburgh 12-0-Tetradecanoyl phorbol-13-acetate induced differentiation in human lung squamous carcinoma cells.

J. Smyth, S. Langdon, W. Miller, 2007 .

University of Rochester--leaders in heavy metals.

J. Smyth, S. Langdon, W. Miller, 1993, Environmental health perspectives.

12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells.

J. Smyth, S. Langdon, W. Miller, 1992, British Journal of Cancer.

Inhibition of cell signalling pathways.

J. Smyth, S. Langdon, 1995, Cancer treatment reviews.

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer

D. Harrison, Rui Huang, P. Mullen, 2015, Oncotarget.

The role of HDAC 2 in chromatin remodelling and response to chemotherapy in ovarian cancer

Harrison, Rui Huang, P. Mullen, 2015 .

Estrogen regulation of transforming growth factor-α in ovarian cancer

S. Langdon, W. Miller, G. Hirst, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features.

D. Burns, S. Langdon, W. Miller, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes.

D. Burns, S. Langdon, W. Miller, 1995, European journal of cancer.

Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.

J. Bartlett, J. Smyth, S. Langdon, 1992, British Journal of Cancer.

Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines.

S. Langdon, W. Miller, A. J. Crew, 1992, European journal of cancer.

Determination of two neuropeptide growth factor antagonists, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P and [Arg6,D-Trp7,9,N-MePhe8]- substance P(6-11), by high-performance liquid chromatography with electrochemical detection.

J. Smyth, S. Langdon, E. Rozengurt, 1994, Journal of chromatography. B, Biomedical applications.

Correlation between the Molecular Weight and Potency of Polar Compounds Which Induce the Differentiation of HL-60 Human Promyelocytic Leukemia Cells1

J. Hickman, S. Langdon, 2006 .

Correlation between the molecular weight and potency of polar compounds which induce the differentiation of HL-60 human promyelocytic leukemia cells.

J. Hickman, S. Langdon, 1987, Cancer research.

Biology of Female Cancers

A. Berchuck, S. Langdon, W. Miller, 1997 .

Targeting HER2-Driven Cancers in Non-Breast Cancer Malignancies

S. Langdon, 2012 .

Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.

J. Bartlett, J. Smyth, S. Langdon, 1992, British Journal of Cancer.

Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon.

P. Mullen, S. Langdon, W. Miller, 1991, British Journal of Cancer.

The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.

O. Fodstad, S. Langdon, H. Fiebig, 1998, European journal of cancer.

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

D. Cameron, D. Harrison, R. L. Hayward, 2022, Exploration of targeted anti-tumor therapy.

Progressive Loss of Estrogen Receptor α Cofactor Recruitment in Endocrine Resistance

R. Clarke, D. Cameron, S. Langdon, 2007 .

Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.

J. Smyth, S. Langdon, S. Lawrie, 1988, Cancer research.

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors

Deeni, S. Langdon, Y. Deeni, 2021, Exploration of targeted anti-tumor therapy.

Tamoxifen increases apoptosis but does not influence markers of proliferation in an MCF-7 xenograft model of breast cancer.

M. Arends, S. Langdon, W. Miller, 2000, Breast.

BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland.

D. Fitzpatrick, P. Mullen, S. Langdon, 1997, British Journal of Cancer.

Brcai 5382insc Mutation in Sporadic and Familial Breast and Ovarian Carcinoma in Scotland Materials and Methods Subjects Dna Extraction from Tumours

D. Fitzpatrick, P. Mullen, S. Langdon, 2022 .

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.

H. Gabra, J. Bartlett, J. Smyth, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Isolation and culture of ovarian cancer cell lines.

S. Langdon, 2004, Methods in molecular medicine.

Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868

J. Bartlett, J. Smyth, S. Langdon, 1999, British Journal of Cancer.

Edinburgh Research Explorer Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anticancer therapy

Hilal S. Khalil, J. Bown, D. Harrison, 2018 .

The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell lines

J. Smyth, S. Langdon, W. Miller, 1994, The Journal of Steroid Biochemistry and Molecular Biology.

Contrasting effects of 17 β‐estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo

J. Smyth, S. Langdon, W. Miller, 1993 .

Estrogen-responsive ovarian cancer xenografts.

S. Langdon, A. Ritchie, 2001, Methods in molecular medicine.

Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study.

O. Fodstad, S. Langdon, H. Fiebig, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy.

J. Hickman, M. Stevens, S. Langdon, 1985, European journal of cancer & clinical oncology.

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)

S. Langdon, A. Ritchie, J. Smyth, 2002, British Journal of Cancer.

Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo [ 5 , l-onl , 2 , 3 , 5-tetrazin-4 ( 37 / )-one ( CCRG 81045 ; M & B 39831 ) , a Novel Drug with Potential as an Alternative to Dacarbazine 1

J. Hickman, Christopher, M. Stevens, 2006 .

Edinburgh Research Explorer HER2 regulates HIF-2 and drives an increased hypoxic response in breast cancer

C. Ward, A. Turnbull, S. Langdon, 2019 .

The Importance of Growth Factors and Steroid Hormones in Ovarian Cancer

D. Harrison, S. Langdon, D. Faratian, 2009, Oncology Research and Treatment.

Endothelin expression and responsiveness in human ovarian carcinoma cell lines.

S. Langdon, W. Miller, S. Moraitis, 1997, European journal of cancer.

Processing of [d-Arg1,d-Phe5,d-Trp7,9,Leu11]Substance P in Xenograft Bearing Nu/Nu Mice

J. Smyth, S. Langdon, A. Ritchie, 1997, Peptides.

Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.

M. Broggini, M. D’Incalci, S. Langdon, 1982, Biochemical pharmacology.

Animal modeling of cancer pathology and studying tumor response to therapy.

S. Langdon, 2012, Current drug targets.

Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo

U. Reichert, J. Smyth, S. Langdon, 1998, Cancer Chemotherapy and Pharmacology.

Processing of the neuropeptide growth factor antagonist [Arg6, D-Trp7.9, NmePhe8]-substance P (6-11) by a small cell lung cancer cell line (H69).

J. Smyth, S. Langdon, E. Rozengurt, 1995, Biochemical pharmacology.

Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.

S. Langdon, W. Miller, A. Lessells, 1996, British Journal of Cancer.

c-erbB-3 protein expression in ovarian tumours.

J. Weatherill, S. Langdon, W. Miller, 1995, British Journal of Cancer.

The use of matrigel in the establishment of ovarian carcinoma cell lines as xenografts.

P. Mullen, S. Langdon, 2001, Methods in molecular medicine.

Structural studies on bioactive compounds. 4. A structure-antitumor activity study on analogues of N-methylformamide.

J. Hickman, M. Stevens, S. Langdon, 1986, Journal of medicinal chemistry.

Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.

Adam J Pawson, S. Langdon, Stuart Maudsley, 2008, Molecular endocrinology.

Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment.

Alan F. Murray, C. Ward, D. Argyle, 2019, Current topics in microbiology and immunology.

The formation and metabolism of N-hydroxymethyl compounds--IV. Cytotoxicity and antitumour activity of N-hydroxymethylformamide, a putative metabolite of N-methylformamide (NSC 3051).

J. Hickman, M. Stevens, S. Langdon, 1983, Biochemical pharmacology.

Basic principles of cancer cell culture.

S. Langdon, 2004, Methods in molecular medicine.

Mammalian Cell Culture

S. Langdon, 2008 .

Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.

J. Hickman, M. Stevens, S. Langdon, 1985, Cancer research.

The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination

S. Langdon, J. Ishmael, E. Harpur, 2004, Cancer Chemotherapy and Pharmacology.

Alkylformamides as inducers of tumour cell differentiation--a mini-review.

J. Hickman, S. Langdon, 1987, Toxicology.

Studies on the toxicity of the antitumour agent N-methylformamide in mice.

J. Hickman, M. Stevens, S. Langdon, 1985, Toxicology.

N-methylformamide: antitumour activity and metabolism in mice.

J. Hickman, D. Ross, S. Langdon, 1982, British Journal of Cancer.

Establishment of ovarian cancer cell lines.

S P Langdon, S. Langdon, S. Lawrie, 2001, Methods in molecular medicine.

Characterization and properties of nine human ovarian adenocarcinoma cell lines.

J. Smyth, S. Langdon, S. Lawrie, 1988, Cancer research.

Antisense Oligonucleotide Targeting of Raf-1

B. Monia, J. Smyth, P. Mullen, 2004, Clinical Cancer Research.

Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography.

J. Smyth, S. Langdon, J. Cummings, 1994, Journal of pharmaceutical and biomedical analysis.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

S P Langdon, C. G. Newton, R Stone, 1987, Cancer research.

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies

S. Langdon, Y. Deeni, P. Paramasivan, 2019, Cancer drug resistance.

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen

Azusa Yamaguchi, Galina Lebedeva, Simon P. Langdon, 2012, BMC Systems Biology.

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer

M. Arends, S. Langdon, Sarah J. Taylor, 2020, Exploration of targeted anti-tumor therapy.

Predictive markers of endocrine response in breast cancer

C. Ward, A. Turnbull, S. Langdon, 2018, World journal of experimental medicine.

Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy

D. Harrison, P. Mullen, S. Langdon, 2011, PloS one.

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

D. Harrison, P. Mullen, S. Langdon, 2011, European journal of cancer.

Cancer systems biology.

David J Harrison, V. Smith, J. Bown, 2016, Methods in molecular biology.

The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer

P. Edwards, J. Brenton, K. Howe, 2012, The Journal of pathology.

Pertuzumab for the treatment of metastatic breast cancer

D. Cameron, S. Langdon, 2013, Expert review of anticancer therapy.

Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system

V. Anne Smith, Simon P. Langdon, David J. Harrison, 2015 .

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

C. Ward, A. Turnbull, S. Langdon, 2018, BMC Cancer.

Endocrine therapy in epithelial ovarian cancer

H. Gabra, S. Langdon, C. Gourley, 2017, Expert review of anticancer therapy.

Development and characterisation of acquired radioresistant breast cancer cell lines

Alan F. Murray, C. Ward, A. Turnbull, 2019, Radiation Oncology.

Explorer Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma

Thomas J. Hardcastle, D. Huntsman, J. Brenton, 2017 .

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma

Thomas J. Hardcastle, David Huntsman, Nataliya Melnyk, 2010, Oncogene.

HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis

D. Harrison, S. Langdon, I. Um, 2012, Journal of Clinical Pathology.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib

Hilal S. Khalil, J. Bown, S. Langdon, 2017, Oxidative medicine and cellular longevity.

AntÂ¡tumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl- imidazo[5,l-on-l,2,3,5-tetrazin-4(37/)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine1

J. Hickman, Christopher, M. Stevens, 2006 .

Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.

Abdul-Malek S. Al-Tamimi, C. Supuran, M. Ferraroni, 2019, European journal of medicinal chemistry.

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

S. Langdon, A. Sims, Maria Bonello, 2018, Cancer biology & medicine.

Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

O. Fodstad, S. Langdon, H. Fiebig, 1992, Cancer research.

Chapter 4 Acquired and Intrinsic Resistance to Colorectal Cancer Treatment

D. Harrison, Romina Briffa, G. Grech, 2018 .

Acquired and intrinsic resistance to colorectal cancer treatment

D. Harrison, Romina Briffa, G. Grech, 2017 .

Cell culture contamination: an overview.

S. Langdon, Simon P Langdon, 2004, Methods in molecular medicine.

Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer

John F Smyth, D. Cameron, J. Smyth, 2007, Clinical Cancer Research.

Insulin-like Growth Factor Binding Proteins IGFBP 3 , IGFBP 4 , and IGFBP 5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer

D. Cameron, J. Smyth, S. Langdon, 2007 .

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.

D. Cameron, J. Smyth, S. Langdon, 2007, Gynecologic oncology.

Pertuzumab for the treatment of ovarian cancer

D. Harrison, P. Mullen, S. Langdon, 2010, Expert opinion on biological therapy.

HER2-Targeted Antibody Treatment for Ovarian Cancer Future Opportunities

S. Langdon, A. Sims, 2016 .

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

D. Cameron, J. Smyth, P. Mullen, 2007, Molecular Cancer Therapeutics.

Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow.

C. Ward, I. Kunkler, S. Langdon, 2015, Breast.

Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice.

D. Burns, J. Cummings, S. Langdon, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Personalisation of Radiotherapy for Breast Cancer

F. Feng, L. Pierce, C. Ward, 2016 .

Antitumour activity and schedule dependency of 8-chloroadenosine-3',5'-monophosphate (8-ClcAMP) against human tumour xenografts.

S. Langdon, W. Miller, P. Stockman, 1998, European journal of cancer.

Edinburgh Research Explorer Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

D. Wilson, S. Langdon, D. Faratian, 2022 .

The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers

B. Vojtesek, R. Nenutil, A. Fourtouna, 2010, Oncogene.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

Hilal S. Khalil, J. Bown, D. Harrison, 2016, Oncotarget.

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

D. Burns, J. Smyth, S. Langdon, 2005, Endocrine-related cancer.

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer

R. L. Hollis, S. Langdon, C. Herrington, 2020, Cancers.

Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.

H. Gabra, J. Smyth, S. Langdon, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transforming growth factor-P mRNA expression andgrowth control of humanovarian carcinoma cells

J. Bartlett, J. Smyth, S. Langdon, 1992 .

Characterization and authentication of cancer cell lines: an overview.

S. Langdon, 2004, Methods in molecular medicine.

Transforming growth factor-mRNA expression and growth control of human ovarian carcinoma cells

J. Bartlett, J. Smyth, S. Langdon, 2007 .

Hormone therapy for epithelial ovarian cancer

John F Smyth, J. Smyth, S. Langdon, 2008, Current opinion in oncology.

Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer

Liang Liang, David J Harrison, D. Cameron, 2010, Breast Cancer Research.

The impact of tumour pH on cancer progression: strategies for clinical intervention

Alan F. Murray, C. Ward, D. Argyle, 2020, Exploration of targeted anti-tumor therapy.

Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo.

D. Harrison, P. Mullen, S. Langdon, 2008, Cancer research.

The chemosensitivity of a new experimental model--the M5076 reticulum cell sarcoma.

J. Hickman, M. Stevens, S. Langdon, 1984, European journal of cancer & clinical oncology.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

R. Clarke, D. Cameron, S. Langdon, 2006, Endocrine-related cancer.

Estrogen Receptor Signaling in Cancer

S. Langdon, 2020, Cancers.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer

C. Ward, A. Turnbull, S. Langdon, 2019, Breast Cancer Research.

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated NDRG1-Driven Proliferation in Triple-Negative Breast Cancer

S. Langdon, A. Sims, A. Mishra, 2020, Breast cancer : basic and clinical research.

Expression of the Heat Shock Protein H5P27 in Human Ovarian Cancer

J. Smyth, S. Langdon, W. Miller, 1995 .

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models

C. Ward, A. Turnbull, D. Harrison, 2016, British Journal of Cancer.

Investigation of the role of ROS modulation in the antitumour effect of a novel breast cancer drug

C. Ward, D. Harrison, P. Mullen, 2014 .

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation

S. Langdon, D. Faratian, K. Morgan, 2012, Endocrine-related cancer.

Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness

C. Ward, D. Argyle, I. Kunkler, 2018, Metabolites.

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

C. Supuran, C. Ward, A. Turnbull, 2017, Oncotarget.

Oncotarget paper published

C. Supuran, C. Ward, A. Turnbull, 2017 .

Explorer Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

C. Supuran, C. Ward, A. Turnbull, 2017 .

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models

P. Lambin, L. Dubois, C. Supuran, 2015, Oncotarget.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

Hilal S. Khalil, J. Bown, S. Langdon, 2015, Oxidative medicine and cellular longevity.

Dynamic Reprogramming of Signalling Networks - A New Challenge in Cancer Therapy

J. Bown, D. Harrison, S. Langdon, 2014 .

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

J. Bown, D. Harrison, S. Langdon, 2013, Cellular signalling.

Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

D. Harrison, P. Mullen, S. Langdon, 2011, Clinical Cancer Research.

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

D. Harrison, P. Mullen, S. Langdon, 2009, Molecular Cancer Research.

Role of post-translational regulation pten activity in cancer cell addiction to heterozygous mutations

Hilal S. Khalil, J. Bown, D. Harrison, 2013 .

Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance.

David R Goodlett, Jean O'Donoghue, D. Goodlett, 2011, Journal of proteome research.

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors

S. Langdon, Y. Deeni, P. Paramasivan, 2021, Exploration of targeted anti-tumor therapy.

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

V. Smith, D. Harrison, S. Langdon, 2016, BMC Cancer.

Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer

V. Smith, D. Harrison, S. Langdon, 2014, British Journal of Cancer.

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis

V. Smith, D. Harrison, S. Langdon, 2015, Scientific Reports.

Cancer Therapy: Preclinical Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

D. Harrison, P. Mullen, S. Langdon, 2011 .

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

J. Smyth, P. Mullen, S. Langdon, 2005, Cancer research.

Cisplatin-Resistant Ovarian Cancer Altered ErbB Receptor Signaling and Gene Expression in

J. Smyth, P. Mullen, S. Langdon, 2005 .

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models

C. Ward, A. Turnbull, S. Langdon, 2015, Oncotarget.

Expression of the heat shock protein HSP27 in human ovarian cancer.

J. Smyth, S. Langdon, W. Miller, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models

D. Harrison, S. Langdon, I. Um, 2019, Scientific Reports.

Implantable biosensors and their contribution to the future of precision medicine.

Alan F. Murray, M Gray, J Meehan, 2018, Veterinary journal.

Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer

D. Harrison, Rui Huang, S. Langdon, 2014, PloS one.

Increased STAT 1 Signaling in Endocrine-Resistant Breast Cancer

D. Harrison, Rui Huang, S. Langdon, 2014 .

Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.

P. Mullen, S. Langdon, W. Miller, 1996, International journal of cancer.

In vivo and In vitro Context Affect Tumor Cell Responses to Agonist Gonadotropin-Releasing Hormone Receptor Levels and Cell

D. Harrison, P. Mullen, S. Langdon, 2008 .

Human ovarian cancer cells: interaction with Tetrachlorodibenzo-p-dioxin (TCDD)

S. Safe, S. Langdon, W. Miller, 1992 .

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

David J Harrison, Colette Meyer, Kevin Morgan, 2011, BMC Cancer.

Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines.

S. Safe, S. Langdon, X. Wang, 1993, Cancer research.

Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.

D. Ross, M. Stevens, S. Langdon, 1984, Biochemical pharmacology.

GnRH analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand- induced-selective-signalling

Adam J Pawson, S. Langdon, K. Morgan, 2008 .

Paracrine regulation of ovarian cancer by endothelin.

J. Smyth, S. Langdon, W. Miller, 1999, European journal of cancer.

Neuregulin expression, function, and signaling in human ovarian cancer cells.

J. Smyth, W. Gullick, S. Langdon, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization and authentication of cancer cell lines: an overview.

S. Langdon, Simon P Langdon, 2004, Methods in molecular medicine.

The stereochemical course of amino acid activation by methionyl- and tyrosyl-tRNA synthetases

S. Langdon, G. Lowe, 1979, Nature.

Metabolism of the anticancer peptide: H-Arg-d-Trp-NmePhe-d-Trp-Leu-Met-NH2

J. Smyth, S. Langdon, E. Rozengurt, 1995, Peptides.

Transforming growth-factor-Beta (tgf-Beta) messenger-RNA expression and growth-control in human lung squamous carcinoma cell-lines.

J. Bartlett, S. Langdon, W. Miller, 1994, International journal of oncology.

Effect of matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines

P. Mullen, S. Langdon, W. Miller, 1996 .

Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

J. Smyth, W. Gullick, S. Langdon, 2001, Cancer research.

Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.

J. Smyth, S. Langdon, E. Rozengurt, 1996, British Journal of Cancer.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer

C. Ward, A. Turnbull, S. Langdon, 2019, Breast Cancer Research.

Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G.

J. Smyth, S. Langdon, David Ackley Jones, 1997, General pharmacology.

Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2.

J. Smyth, S. Langdon, David Ackley Jones, 1995, Biochemical pharmacology.

Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograft.

J. Smyth, S. Langdon, E. Rozengurt, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

D. Harrison, S. Langdon, I. Um, 2013, Gynecologic oncology.

Cancer Cell Culture: Methods and Protocols

S. Langdon, 2018, Methods in Molecular Biology.

Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance.

R. Clarke, D. Cameron, S. Langdon, 2007, Molecular endocrinology.

Investigations of the relationship between cell proliferation and differentiation of HL-60 cells induced to differentiate by N-methylformamide.

J. Hickman, S. Langdon, F. Richards, 1988, Leukemia research.

Ovarian cancer models : technical review.

J. Bartlett, S. Langdon, J. Edwards, 2001, Methods in molecular medicine.

Variation in IL6ST cytokine family function and the potential of IL6 trans-signalling in ERα positive breast cancer cells.

A. Turnbull, S. Langdon, K. Macleod, 2022, Cellular signalling.

Ovarian Cancer: Methods and Protocols

John M. S. Bartlett, Simon P. Langdon, J. Bartlett, 2000, Methods in Molecular Biology.

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

D Faratian, D. Harrison, S. Langdon, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma

F. Couch, E. Swisher, T. Taniguchi, 2009 .

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models

C. Ward, A. Turnbull, S. Langdon, 2015 .

Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts.

O. Fodstad, S. Langdon, H. Fiebig, 1992, European journal of cancer.

Estrogen regulation of transforming growth factor-alpha in ovarian cancer.

J. Bartlett, J. Smyth, S. Langdon, 1998, The Journal of steroid biochemistry and molecular biology.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer

D. Harrison, S. Langdon, I. Um, 2012, British Journal of Cancer.

Role of TGFα stimulation of the ERK, PI3 kinase and PLCγ pathways in ovarian cancer growth and migration

J. Smyth, S. Langdon, J. Sewell, 2005 .

Oncotarget paper published

C. Supuran, C. Ward, A. Turnbull, 2017 .

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Stuart L. Moodie, I. Goryanin, A. Sorokin, 2009, Cancer research.

Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

D. Harrison, P. Mullen, S. Langdon, 2011, Clinical Cancer Research.

Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas

S. Langdon, S. Hillier, M. Rae, 2005, British Journal of Cancer.

Modulation of the cluster 1 and mucin antigens in human small cell lung cancer and other epithelial tumour cell lines after treatment with the differentiation inducing agent, sodium butyrate.

S. Langdon, R. Leonard, F. G. Hay, 1991, The British journal of cancer. Supplement.

Personalisation of Radiotherapy for Breast Cancer

E. Winer, I. Kunkler, C. Speers, 2016 .

Growth factors and receptors in ovarian cancer

S. Langdon, R. Leake, O. Owens, 1995 .